Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 18/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 14/20 | 0.49 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4532094 | 0.85 | TLR7 (0.57) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL29385735 | 0.85 | TLR7 (0.57) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL7231032 | 0.83 | TLR7 (0.42) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL7231973 | 0.83 | AVPR1A (0.40) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL2749843 | 0.83 | MEN1 (0.36) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL5617306 | 0.82 | TLR8 (0.35) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL30612932 | 0.81 | TLR7 (0.46) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL21712347 | 0.81 | TLR7 (0.46) | TLR7TLR8NUDT1MEN1KMT2A | |
| SCHEMBL1895061 | 0.81 | TLR7 (0.56) | TLR7TLR8NUDT1MEN1TSHR | |
| SCHEMBL4156827 | 0.79 | ENPP2 (0.32) | TLR7TLR8NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846710-B2 | Method of preferentially inducing the biosynthesis of interferon | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2014-09-30 | — | — | US | disclosed |
| US-8343993-B2 | Hydroxyalkyl substituted imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2013-01-01 | — | — | US | disclosed |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC, (US) | 2009-10-08 | — | — | US | disclosed |
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| EP-1851220-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M Innovative Properties Company (US) | 2007-11-07 | — | — | EP | disclosed |
| EP-1850849-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | Coley Pharmaceutical Group, Inc. (US) | 2007-11-07 | — | — | EP | disclosed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091568-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030031-A1 | Method of Preferentially Inducing the Biosynthesis of Interferon | IFNG, IFNAR1, EIF2AK2 | TLR7 194/4885TLR8 494/4885NUDT1 302/4885 |
| US-20090253695-A1 | Hydroxyalkyl Substituted Imidazonaphthyridines | IFNG, IFNAR1, IRF3 | TLR7 68/4885TLR8 187/4885NUDT1 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.